Ben Adams / FierceBiotech
FDA Commissioner Scott Gottlieb, M.D., has hit back at plans that could see the Pentagon take control over the approval of some experimental drugs and devices for soldiers.
A new policy from the Senate’s National Defense Authorization Act, which is going through committee, would allow the Pentagon to approve devices and drugs not green-lit by FDA to be used on military personnel “for emergency use.” The plans were first published this week by Politico.
But Gottlieb has hit back at the plans, believing this should be left with his agency, as is currently the case.
“That's important because we think we provide a level of oversight that helps ensure the safety of products, helps follow-up to make sure that if there are adverse events we're monitoring them, we're collecting that information,” Gottlieb said at a The Hill event on Tuesday. “So, we think keeping it within the FDA context is the right thing.”
It had offered a plan B in which FDA would still have control but could see it speed up approval through talks with the Department of Defense (DOD), but this wasn’t accepted.
Some have criticized the plans for undermining the FDA. This issue has centered on the FDA’s rejection of freeze-dried plasma, something the Pentagon says is necessary to save the lives of military personnel.
“FDA has been working closely with DOD to bring freeze-dried plasma to our troops and anticipates that these products will be fully approved for safe and effective use for our armed forces as early as 2018,” an agency official told Politico this week.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.